Kezar's ongoing Phase 2a PORTOLA clinical trial of zetomipzomib in patients with autoimmune hepatitis has completed enrollment and remains active at this time (Businesswire) - Sep 30, 2024 - "To date, no Grade 4 or 5 SAEs have been observed in the PORTOLA clinical trial."
Enrollment closed • Autoimmune Hepatitis
|